The High Price Of Bad BloodDavid Greising
It looks as though Baxter International Inc. is about to take another hit. Within weeks, it may be forced to reserve hundreds of millions of dollars to help redress one of the saddest accidents in medical history: the infection of thousands of hemophiliacs with HIV-tainted blood-clotting products.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Ford to Take $267 Million Hit From Recall of F-Series Trucks
- Gulf Coast Oil Spill May Be Largest Since 2010 BP Disaster
- Facebook and Google Helped Anti-Refugee Campaign in Swing States